TrialInternational journal of clinical oncology2022

A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.

Susana Campos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.